More than 200 lots of irbesartan, losartan and valsartan recalled in Canada
Multiple lots of irbesartan, losartan and valsartan have been recalled in Canada due to the presence of an azido impurity above the acceptable limit. The impurity is a mutagen and can create a heightened cancer risk over time if allowed to rise above certain levels.
This new recall includes more than 200 lots of the medications manufactured by nine different companies. The affected companies are Auro Pharma, Mint Pharmaceuticals, Pharmascience, Pro Doc, Sandoz Canada, Sanis Health, Sivem Pharmaceuticals ULC, Sun Pharma Canada and Teva Canada.
Health Canada announced the news in an advisory, noting that patients should continue taking these medications unless they have specifically been advised to stop by their healthcare provider.
“Not all lots of irbesartan, losartan and valsartan from these companies are affected by this issue; however, it is possible that the recalls may affect the supply of some products,” according to Health Canada. “Patients should speak with their doctor or pharmacist to discuss alternatives should their regular prescribed drug not be available.”
Read the full advisory here.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.